A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

计划入组 40 人 · 首次发布于 2026 年 1 月 21 日

EMDR on Pain in Patients With in Patients Rheumatoid Arthritis

计划入组 64 人 · 首次发布于 2023 年 7 月 13 日

Clinical Performance of BIS-GMA Free Dental Resin Composite

计划入组 40 人 · 首次发布于 2022 年 7 月 29 日

FoRx-06-428

thalassemia therapeutics

PGTI-0306 based therapeutics (Phenogene Therapeutics)

JASPER THERAPEUTICS, INC

United States

CRISPR Therapeutics, Inc.

United States

Rani Therapeutics, LLC

United States

FoRx Therapeutics Doses First Patient with Novel PARG Inhibitor FORX-428 in Phase 1 Cancer Trial

FoRx Therapeutics Secures $50M Series A to Advance PARG Inhibitor for PARP-Resistant Cancers

Engitix Secures €21 Million Series A Extension to Advance ECM-Targeted Cancer and Fibrosis Therapies